Astrana Health (ASTH) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Mission and Industry Context

• Focused on empowering providers to deliver high-quality, coordinated care and address systemic inefficiencies in U.S. healthcare, transforming fragmented, fee-for-service models into integrated, value-based networks.

• Operates across multiple payers and lines of business, including Medicare, Medicaid, and commercial plans, serving 1.1 million value-based lives with a diverse demographic mix.

• Seeks to bend the healthcare cost curve through risk-bearing arrangements, technology, and delegated financial models, investing in longitudinal patient health.

• Emphasizes long-term investment in patient health, continuity of care, and reducing administrative burden for providers.

• Technology-driven care coordination and data infrastructure enhance patient access, provider efficiency, and result in shorter inpatient stays and fewer hospital admissions than benchmarks.

Business Model and Operations

• Functions as a pseudo-single payer, aggregating premium dollars and managing both financial and clinical outcomes, leveraging a delegated financial model.

• Contracts with over 25 payers, taking on up to 85% of premium dollars and full risk for patient populations, with a goal of 70% full-risk membership by 2025.

• Owns and operates around 70 clinical locations, supplementing asset-light contracted networks, and supports robust provider retention (98%).

• Offers technology-enabled services for care enablement, streamlining provider workflows and administrative tasks, and automating 70% of prior authorizations.

• Providers benefit from reduced administrative burden, centralized support, and higher panel penetration.

Growth Strategy, Expansion, and Financial Performance

• Achieved 29% CAGR in revenue and 26% CAGR in EBITDA since 2019, with 2024 guidance of $1.95–$2.03B revenue and $165–$175M Adjusted EBITDA.

• Pro forma, expects to reach 1.7 million members, $3.2B in 2024 pro forma revenue, and $251M in pro forma Adjusted EBITDA post-acquisition.

• Guides to at least $350M Adjusted EBITDA for full year 2027, assuming conservative growth rates.

• Segment results for Q3 2024 show strong revenue growth across Care Partners (42%), Care Delivery (20%), and Care Enablement (11%).

• Cash and investments increased to $350.3M as of September 30, 2024, with total stockholders' equity at $709.6M.